Xiaolei Ren

Xiaolei Ren


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2019 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
CZChenghao Zhang
Chenghao Zhang
XRXiaolei Ren
Xiaolei Ren
JHJieyu He
Jieyu He
WWWanchun Wang
Wanchun Wang
Chao TuChao Tu
Chao Tu
ZLZhihong Li
Zhihong Li
Background: Cancer has been a worldwide health problem with a high risk of morbidity and mortality, however ideal biomarkers for effective screening and diagnosis of cancer patients are still lacking. Small nucleolar RNA host gene 16 (SNHG16) is newly identified lncRNA with abnormal expression in several human malignancies. However, its prognostic value remains controversial. This meta-analysis aimed to synthesize available data to clarify the association between SNHG16 expression levels and clinical prognosis value in multiple cancers. Methods: Extensive literature retrieval was conducted to identify eligible studies, and data regarding SNHG16 expression levels on survival outcomes and clinicopathological features were extracted and pooled for calculation of the hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs). Forest plots were applied to show the association between SNHG16 expression and survival prognosis. Additionally, The Cancer Genome Atlas (TCGA) dataset was screened and extracted for validation of the results in this meta-analysis. Results: A total of eight studies comprising 568 patients were included in the final meta-analysis according to the inclusion and exclusion criteria. In the pooled analysis, high SNHG16 expression significantly predicted worse overall survival (OS) in various cancers (HR = 1.87, 95% CI 1.54–2.26, P < 0.001), and recurrence-free survival (RFS) in bladder cancer (HR = 1.68, 95% CI 1.01–2.79, P = 0.045). Meanwhile, stratified analyses revealed that the survival analysis method, tumor type, sample size, and cut-off value did not alter the predictive value of SNHG16 for OS in cancer patients. In addition, compared to the low SNHG16 expression group, patients with high SNHG16 expression were more prone to worse clinicopathological features, such as larger tumor size, advanced clinical stage, lymph node metastasis (LNM) and distant metastasis (DM). Exploration of TCGA dataset further validated that the upregulated SNHG16 expression predicted unfavorable OS and disease-free survival (DFS) in cancer patients. Conclusions: The present study implicated that aberrant expression of lncRNA SNHG16 was strongly associated with clinical survival outcomes in various cancers, and therefore might serve as a promising biomarker for predicting prognosis of human cancers.

6 June 2025 in Advanced Science
Verified
Journal Article
Open access
RXRuiling Xu
Ruiling Xu
SZSai Zhu
Sai Zhu
WZWenchao Zhang
Wenchao Zhang
HXHaodong Xu
Haodong Xu
CTChao Tu
Chao Tu
ZLZhihong Li
Zhihong Li
Osteosarcoma (OS), the most prevalent primary bone malignancy in adolescents, is typically treated with cisplatin‐based chemotherapy. However, the development of cisplatin resistance often leads to relapse or metastasis, significantly impairing therapeutic efficacy. To tackle this issue, patient‐derived osteosarcoma organoids (OSOs) is established that accurately reflect the cellular composition and heterogeneity of the original tumors, as validated by single‐cell RNA sequencing, bulk RNA sequencing, and histopathology analysis. Cisplatin resistance is successfully induced in these OSOs, creating a clinically relevant model for investigating chemoresistance. Utilizing RNA sequencing in cisplatin‐resistance OSOs and CRISPR screening in OS cell line, ERCC6 is identified as a pivotal regulator of cisplatin resistance. Knockdown of ERCC6 markedly enhanced cisplatin sensitivity in vitro and in vivo. Mechanistically, ERCC6 interacts with HNRNPM, influencing the PI3K/AKT signaling pathway and alternative splicing of pre‐mRNA for BAX. Notably, the knockdown of ERCC6 and HNRNPM increased expression of full‐length BAX and reduced skipping of exon 2, thus promoting apoptosis. This exon skipping in BAX results in a frameshift and introduces a premature stop codon (TGA) within the BH3 domain. These findings underscore the utility of OSOs in elucidating resistance mechanisms and highlight ERCC6 and HNRNPM as potential therapeutic targets.

4 October 2023 in Phenomics
Verified
Journal Article
Closed access
PDF file
RXRuiling Xu
Ruiling Xu
RCRuiqi Chen
Ruiqi Chen
Chao TuChao Tu
Chao Tu
XGXiaofeng Gong
Xiaofeng Gong
ZLZhongyue Liu
Zhongyue Liu
ZLZhihong Li
Zhihong Li

18 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
RXRuiling Xu
Ruiling Xu
Lin QiLin Qi
Lin Qi
XRXiaolei Ren
Xiaolei Ren
WZWenchao Zhang
Wenchao Zhang
CLChenbei Li
Chenbei Li
ZLZhihong Li
Zhihong Li
Soft tissue sarcoma (STS) is one of the rarest but most aggressive cancer. It is important to note that intratumoral hypoxia and tumor microenvironment (TME) infiltration play a significant role in the growth and therapeutic resistance of STS. The goal of this study was therefore to determine whether linking hypoxia-related parameters to TME cells could provide a more accurate prediction of prognosis and therapeutic response. An analysis of 109 hypoxia-related genes and 64 TME cells was conducted in STS. Hypoxia-TME classifier was constructed based on 6 hypoxia prognostic genes and 8 TME cells. As a result, we evaluated the prognosis, tumor, and immune characteristics, as well as the effectiveness of therapies in Hypoxia-TME-defined subgroups. The Lowplus group showed a better prognosis and therapeutic response than any other subgroup. It is possible to unravel these differences based on immune-related molecules and somatic mutations in tumors. Further validation of Hypoxia-TME was done in an additional cohort of 225 STS patients. Additionally, we identified five key genes through differential analysis and RT-qPCR, namely, ACSM5, WNT7B, CA9, MMP13, and RAC3, which could be targeted for therapy. As a whole, the Hypoxia-TME classifier demonstrated a pretreatment predictive value for prognosis and therapeutic outcome, providing new approaches to therapy strategizing for patients.

19 November 2024 in Oncogene
Verified
Journal Article
Closed access
PDF file
WZWenchao Zhang
Wenchao Zhang
LQLin Qi
Lin Qi
HXHaodong Xu
Haodong Xu
CYChi Yin
Chi Yin
ZYZhuowen Yu
Zhuowen Yu
ZLZhihong Li
Zhihong Li

31 December 2025 in Molecular Therapy Oncology
Verified
Journal Article
Open access
SZSai Zhu
Sai Zhu
RXRuiling Xu
Ruiling Xu
HXHaodong Xu
Haodong Xu
YWYu Wang
Yu Wang
LWLu Wang
Lu Wang
XRXiaolei Ren
Xiaolei Ren
Immunotherapy has revolutionized cancer treatment by harnessing the immune system against malignancies; however, traditional antibody-based therapies are hampered by high production costs, immunogenicity, and off-target effects. Aptamers—short, single-stranded DNA or RNA molecules—have emerged as a promising alternative due to their high affinity and specificity, low immunogenicity, ease of chemical synthesis, and versatile structural modifications. These properties position aptamers as powerful tools for targeted drug delivery, immune modulation, and precision cancer therapy. This review highlights recent advances in aptamer-based cancer immunotherapy, focusing on their structural evolution, responsiveness to the tumor microenvironment, and roles in regulating the immune checkpoint. We highlight the development of monospecific, bispecific, and multispecific aptamers, emphasizing their applications in T cell activation, cytokine regulation, and tumor-targeted immune modulation. Additionally, we explore the role of aptamer-based chimeric systems in immunotherapy, including aptamer-small interfering RNA (siRNA) conjugates, aptamer-nanomaterial hybrids, aptamer-drug complexes, and aptamer-exosomes conjugates. Despite progress, challenges remain, such as the need for greater in vivo stability, improved delivery strategies, and optimized multispecific designs. Future research efforts should focus on refining next-generation immune checkpoint-targeting aptamers and expanding their applications in combination immunotherapies. With continued innovation, aptamer-based therapeutics hold the potential to transform cancer immunotherapy, offering safer, more effective, and highly specific treatment options.